Sign in / Join Now
ETFs & Funds
management is doing a terrible job promoting their drugs. Have not heard ANY media coverage from their ALS or
They should be promoting their company/results of the drug trials in ALS and
/WSJ. Have not seen any media coverage.
Add a reply...
Latest StockTalks »
people get CYTK breaking news and analysis by email alert.
Get email alerts on CYTK »
Get latest price
From other sites
Origent Data Sciences And Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures Of Vital Capacity In Patients With ALS
at TheStreet (Wed, 7:30AM)
Cytokinetics Announces Presentations At The International Symposium On ALS/MND
at TheStreet (Fri, 4:00PM)
Cytokinetics Announces Start Of GALACTIC-HF, A Phase 3 Clinical Trial Of Omecamtiv Mecarbil
at TheStreet (Thu, 7:30AM)
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
at TheStreet (Nov 30, 2016)
Cytokinetics To Participate In Upcoming Investor Conferences
at TheStreet (Nov 22, 2016)